Latest Sironax News & Updates

See the latest news and media coverage for Sironax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sironax

Biopharmaceutical company developing treatments for neurodegenerative, inflammatory, and metabolic diseases

sironax.com

Headquarters: Waltham, United States
Founded year: 2017
Company type: Private company
Number of employees: 60–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Sironax

In short: Sironax raised $200 million and received FDA Fast Track designation for its SARM1 inhibitor SIR2501 for peripheral neuropathy.

Company announcements

Today Sironax

Novartis exercises option to acquire Sironax's brain delivery platform

Sironax receives $125 million and retains rights to selected assets while advancing its clinical pipeline with the proceeds.

May 11 Sironax

Sironax's SIR2501 receives FDA Fast Track for CIPN

The designation facilitates expedited development and review of the therapy for chemotherapy-induced peripheral neuropathy.

April 22 Sironax

Sironax announces SIR2501 abstract acceptance for ASCO 2026

They will present insights on this clinical-stage SARM1 inhibitor as a potential treatment for chemotherapy-induced peripheral neuropathy.

March 26 Sironax

Sironax appoints Clive Wang to Board of Directors

Clive Wang, Managing Director at YF Capital, brings extensive life sciences investment experience. Dr. Shefali Agarwal praises his addition as the company advances clinical programs.

Media coverage

Yesterday Agefi

Novartis acquires brain technology rights from Sironax

The Basel-based group will immediately pay $125 million for this platform designed to cross the blood-brain barrier.

May 12 Kauppalehti

Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025

WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases...

May 11 Yahoo Finance

Sironax's SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment options Fast Track designation reflects the significant unmet need and enables potential...

April 27 PR Newswire

CONCEPT MEDICAL ANNOUNCES 3-YEAR PRELIMINARY DATA FROM SIRONA AT THE CHARING CROSS 2026 SYMPOSIUM

/PRNewswire/ -- Concept Medical Inc., announced today the presentation of preliminary data from the 3-year follow-up of the randomized SIRONA trial at...

Never miss news about Sironax

Track Sironax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sironax competitors & trending companies

Browse news for competitors to Sironax and other trending companies.